Strategic decisions in large organisations are made on research that has rarely been adversarially reviewed. The market entry analysis that depends on a consultant’s assumptions. The vendor claim that hasn’t been triangulated against independent sources. The competitive intelligence that misses the incumbent’s announced response. Augle stress-tests the evidence before the decision is irreversible.
By the time a major strategic decision reaches the board, the evidence base has passed through several layers of internal review — none of which is designed to be adversarial. The consultant who produced the market entry analysis has an interest in the engagement continuing. The vendor whose claims anchor the procurement decision has an interest in winning. Internal strategy teams have an interest in the recommendation they’ve invested months in. Augle has none of these interests.
Questions enterprise teams run on Augle
The Methodologist evaluates every key assumption in a strategy document against the evidence that supports it. A market sizing figure sourced from a single Gartner report, a growth rate projection that compounds an unvalidated base, or a competitive moat argument that doesn’t account for announced incumbent moves — each is identified and graded before the recommendation reaches the board.
The Contrarian evaluates vendor capability and ROI claims against the available independent evidence. A platform that cites proprietary case studies from its own marketing materials as evidence of enterprise ROI, or a vendor whose reference customers were selected by the vendor, receives a different confidence grade than one with independently documented outcomes.
The Cartographer maps the full competitive landscape, not just the evidence the strategy document includes. A competitive analysis that treats the market as static — ignoring announced acquisitions, published roadmaps, or regulatory changes that will reshape the landscape within the decision horizon — is Contested, regardless of how well-sourced its historical data is.
The Contrarian runs at maximum temperature to surface the objection a well-prepared sceptical board member will raise. Unresolved Strong objections appear verbatim with resolution conditions. The strategy team that walks into the board room knowing these questions controls the conversation. The one that hears them for the first time doesn’t.
Each scenario illustrates realistic deliberation behaviour across market entry analysis, vendor evaluation, and competitive intelligence review.
“Does the evidence base in our Southeast Asia market entry analysis support the recommendation to commit £120M over three years, and what are the assumptions the board will challenge?”
The incumbent’s distributor announcement was public. No one on the strategy team had caught it because the analysis was already in the approval process. Finding it before the board presentation cost one week of revision. Finding it in the board room would have cost considerably more — and the recommendation would have been deferred regardless.
“Are the ROI claims in this vendor’s enterprise proposal independently supported, and how should we weight their reference customer evidence?”
The vendor was eventually selected — but at a negotiated contract value that reflected the absence of independent ROI validation in the regulated sector. The procurement team had the evidence to push back on the headline figure. Without Augle, they would have accepted it as stated.
“Does our competitive landscape assessment accurately reflect the threat from the three challenger platforms, and what are we missing?”
The channel partner announcement was in the assessment — in three lines at the end of a section. It deserved its own section and a revised enterprise win rate assumption. The annual plan that went to the board reflected the channel risk. The one that nearly went didn’t.
Upload strategy memos, market analyses, vendor proposals, analyst research, and competitive assessments. Financial and editorial integrity modes activate — the Guardian validates market data recency, source attribution, and the distinction between independent evidence and vendor-supplied claims.
The Cartographer classifies every key claim as Settled, Contested, or Unknown. The Methodologist evaluates whether the evidence supports the conclusions drawn — whether growth rate projections are constructed validly, whether comparable cases are structurally equivalent, whether the analysis accounts for the current competitive landscape.
The Contrarian takes the role of a well-prepared sceptical board member or external advisor — surfacing the strongest version of every challenge to the recommendation. Every objection specifies a resolution condition. Unresolved Strong objections become the preparation agenda before the board presentation.
The Synthesizer produces a finding anchored to the evidence base — not the internal narrative. Confidence grades per key assumption, unresolved objections verbatim, and reopen conditions that specify what new information would change the assessment. The full audit trail is exportable for governance and compliance purposes.
Internal strategy teams have invested months in the recommendation. Consultants have an interest in the engagement continuing. Vendors have an interest in winning. Augle has none of these interests — it produces the finding the evidence supports, not the finding the process has converged on. That independence is the value.
The Contrarian runs the objection a well-prepared sceptical board member will raise — at maximum temperature, with the strongest possible framing. Unresolved Strong objections appear verbatim with resolution conditions. The strategy team that prepares for these questions controls the board conversation. The one that hears them for the first time doesn’t.
Every session produces an exportable audit trail — SVS verification outcomes, confidence grades per assumption, objections raised and their resolution status. For major decisions subject to regulatory scrutiny, shareholder challenge, or post-investment review, this is the record that demonstrates the decision was made on a validated evidence base.
Join the waitlist and run a session on your next major strategic decision.